Sanofi shipping RSV jab Beyfortus in USA

French pharma major Sanofi (Euronext: SAN) today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the USA to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for Children program to help ensure the majority of doses are available ahead of RSV season.

The US market is anticipated to have enough supply so that every eligible baby born outside of the season will have access to immunization at a regular checkup and those born during the season will have access at birth. Beyfortus is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Thomas Grenier, head of vaccines, North America, at Sanofi, commented: "We're proud to offer Beyfortus EYFORTUS doses to help protect every eligible baby in the US this RSV season. This accomplishment aimed at equitable access was made possible through close partnership with the White House, Centers for Disease Control and Prevention, the US Food and Drug Administration, and healthcare providers to make Beyfortus widely available. This upcoming season, we look forward to Beyfortus offering its demonstrated real-world protection to as many infants as possible."